<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: <z:e sem="disease" ids="C0037315" disease_type="Disease or Syndrome" abbrv="">Sleep-disordered breathing</z:e> (SDB) has been associated with various benign <z:hpo ids='HP_0011675'>cardiac arrhythmias</z:hpo> occurring during sleep </plain></SENT>
<SENT sid="1" pm="."><plain>OBJECTIVE: The purpose of this study was to demonstrate that SDB contributes to the development of life-threatening <z:hpo ids='HP_0004308'>ventricular arrhythmias</z:hpo> in patients with an established arrhythmic substrate </plain></SENT>
<SENT sid="2" pm="."><plain>METHODS: We prospectively studied the association between SDB and timing of life-threatening ventricular arrhythmic events in 45 patients with an implantable cardioverter-defibrillator (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e>) </plain></SENT>
<SENT sid="3" pm="."><plain>SDB was defined as an <z:hpo ids='HP_0002104'>apnea</z:hpo>-<z:mp ids='MP_0001956'>hypopnea</z:mp> index (AHI) &gt;10 events/hour based on an overnight sleep study </plain></SENT>
<SENT sid="4" pm="."><plain>The primary outcome measure was appropriate <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> therapy, defined as antitachycardia pacing or shock for <z:hpo ids='HP_0004756'>ventricular tachycardia</z:hpo> or <z:hpo ids='HP_0001663'>ventricular fibrillation</z:hpo> during 1-year follow-up </plain></SENT>
<SENT sid="5" pm="."><plain>RESULTS: SDB was present in 26 (57.8%) patients </plain></SENT>
<SENT sid="6" pm="."><plain>Appropriate <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> therapies were higher among patients with SDB (73% vs 47%, P = .02) </plain></SENT>
<SENT sid="7" pm="."><plain>Logistic regression identified SDB as a predictor of any appropriate <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> therapy (odds ratio 4.4, 95% confidence interval 1.4-15.3, P = .01) </plain></SENT>
<SENT sid="8" pm="."><plain>The risk for <z:hpo ids='HP_0004308'>ventricular arrhythmias</z:hpo> was higher in patients with SDB solely due to an increase in events occurring between midnight and 6 AM (odds ratio 5.6, 95% confidence interval 2.0-15.6, P = .001) with no discernible effect on appropriate <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> therapy during nonsleeping hours (odds ratio 0.7, 95% confidence interval 0.2-2.3, P = .61) </plain></SENT>
<SENT sid="9" pm="."><plain>CONCLUSION: Patients with an <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> and SDB have a striking increase in the <z:hpo ids='HP_0003674'>onset</z:hpo> of life-threatening ventricular arrhythmic events during sleeping hours </plain></SENT>
<SENT sid="10" pm="."><plain>These findings provide a rationale for SDB screening in patients with appropriate <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">ICD</z:e> therapy if device interrogation reveals a predominance of nocturnal <z:hpo ids='HP_0003674'>onset</z:hpo> of <z:hpo ids='HP_0011675'>arrhythmias</z:hpo> </plain></SENT>
</text></document>